EPA Proposes Changes in Determining Cancer Risk of Chemicals, Pollutants

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

WASHINGTON--The Environmental Protection Agency (EPA) is proposing that scientists rely less on animal testing and more on microbiological studies in calculating the cancer risk of chemicals and pollutants. The new regulations would place more emphasis on how chemicals actually affect human cells.

WASHINGTON--The Environmental Protection Agency (EPA) is proposingthat scientists rely less on animal testing and more on microbiologicalstudies in calculating the cancer risk of chemicals and pollutants.The new regulations would place more emphasis on how chemicalsactually affect human cells.

The changes could have a major impact on the country's programsto control pollution and pesticide use. The new regulations werepublished in the Federal Register in April, and will be put intofinal form after completion of 4 months of public comment.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content